Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Operating Expenses (2020 - 2025)

Candel Therapeutics' Operating Expenses history spans 4 years, with the latest figure at $10.3 million for Q4 2023.

  • On a quarterly basis, Operating Expenses rose 26.88% to $10.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $38.4 million, a 10.18% increase, with the full-year FY2025 number at $48.3 million, up 44.63% from a year prior.
  • Operating Expenses hit $10.3 million in Q4 2023 for Candel Therapeutics, up from $8.9 million in the prior quarter.
  • Over the last five years, Operating Expenses for CADL hit a ceiling of $10.3 million in Q4 2023 and a floor of $2.6 million in Q2 2020.
  • Historically, Operating Expenses has averaged $7.4 million across 4 years, with a median of $8.1 million in 2022.
  • Biggest five-year swings in Operating Expenses: skyrocketed 189.93% in 2021 and later decreased 0.57% in 2023.
  • Tracing CADL's Operating Expenses over 4 years: stood at $6.2 million in 2020, then rose by 26.23% to $7.8 million in 2021, then rose by 4.65% to $8.1 million in 2022, then rose by 26.88% to $10.3 million in 2023.
  • Business Quant data shows Operating Expenses for CADL at $10.3 million in Q4 2023, $8.9 million in Q3 2023, and $9.6 million in Q2 2023.